Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stephen Roberts Walsh, M.D.

Title
Institution
Department
Address

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. K23AI085181 (WALSH, STEPHEN R.) Jun 1, 2010 - Apr 30, 2016
    NIH
    Dermatotropic cellular immune responses induced by a novel smallpox vaccine
    Role: Principal Investigator
  2. P51RR000168 (FLIER, JEFFREY S) Jun 1, 1978 - Apr 30, 2013
    NIH
    New England Primate Research Center Base Grant
    Role: Co-Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Cohen KW, Fiore-Gartland A, Walsh SR, Yusim K, Frahm N, Elizaga ML, Maenza J, Scott H, Mayer KH, Goepfert PA, Edupuganti S, Pantaleo G, Hutter J, Morris DE, De Rosa SC, Geraghty DE, Robb ML, Michael NL, Fischer W, Giorgi EE, Malhi H, Pensiero MN, Ferrari G, Tomaras GD, Montefiori DC, Gilbert PB, McElrath MJ, Haynes BF, Korber BT, Baden LR. Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults. J Clin Invest. 2023 02 15; 133(4). PMID: 36787249; PMCID: PMC9927951.
    Citations:    Fields:    Translation:AnimalsCellsPHPublic Health
  2. Dayan GH, Rouphael N, Walsh SR, Chen A, Grunenberg N, Allen M, Antony J, Asante KP, Suresh Bhate A, Beresnev T, Bonaparte MI, Angeles Ceregido M, Dobrianskyi D, Fu B, Grillet MH, Keshtkar-Jahromi M, Juraska M, Jin Kee J, Kibuuka H, Koutsoukos M, Masotti R, Michael NL, Reynales H, Robb ML, Villagómez Martínez SM, Sawe F, Schuerman L, Tong T, Treanor J, Wartel TA, Diazgranados CA, Chicz RM, Gurunathan S, Savarino S, Sridhar S. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine. medRxiv. 2023 Jan 13. PMID: 36523415; PMCID: PMC9753788.
    Citations:    
  3. Mena Lora AJ, Long JE, Huang Y, Baden LR, El Sahly HM, Follmann D, Goepfert P, Gray G, Grinsztejn B, Kotloff K, Rouphael N, Sobieszczyk M, Walsh SR, Andriesen J, Shah KA, Zhang Y, Gilbert P, Janes H, Gay CL, Falsey AR, Tripp RL, Gorman RL, Tong T, Marovich M, Neuzil K, Corey L, Kublin JG. Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. JAMA Netw Open. 2023 Jan 03; 6(1):e2251974. PMID: 36689221.
    Citations:    Fields:    Translation:HumansCellsPHPublic Health
  4. Stieh DJ, Barouch DH, Comeaux C, Sarnecki M, Stephenson KE, Walsh SR, Sawant S, Heptinstall J, Tomaras GD, Kublin JG, McElrath MJ, Cohen KW, De Rosa SC, Alter G, Ferrari G, Montefiori D, Mann P, Nijs S, Callewaert K, Goepfert PA, Edupuganti S, Karita E, Seaman MS, Corey L, Baden LR, Pau MG, Schuitemaker H, Tomaka F. Safety and Immunogenicity of Ad26-vectored HIV Vaccine with Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-uninfected Adults: A Phase 1/2a Study. J Infect Dis. 2022 Nov 09. PMID: 36348617.
    Citations:    Fields:    
  5. Chalkias S, Eder F, Essink B, Khetan S, Nestorova B, Feng J, Chen X, Chang Y, Zhou H, Montefiori D, Edwards DK, Girard B, Pajon R, Dutko FJ, Leav B, Walsh SR, Baden LR, Miller JM, Das R. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nat Med. 2022 11; 28(11):2388-2397. PMID: 36202997; PMCID: PMC9671805.
    Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
  6. Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, Sutherland A, Montefiori DC, Girard B, Edwards DK, Feng J, Zhou H, Baden LR, Miller JM, Das R. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N Engl J Med. 2022 10 06; 387(14):1279-1291. PMID: 36112399.
    Citations: 67     Fields:    Translation:HumansCellsCTClinical Trials
  7. Branche AR, Rouphael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Malkin E, Bethony JM, Walsh EE, Graciaa DS, Samaha H, Sherman AC, Walsh SR, Abate G, Oikonomopoulou Z, El Sahly HM, Martin TCS, Rostad CA, Smith MJ, Ladner BG, Porterfield L, Dunstan M, Wald A, Davis T, Atmar RL, Mulligan MJ, Lyke KE, Posavad CM, Meagher MA, Stephens DS, Neuzil KM, Abebe K, Hill H, Albert J, Lewis TC, Giebeig LA, Eaton A, Netzl A, Wilks SH, Türeli S, Makhene M, Crandon S, Lee M, Nayak SU, Montefiori DC, Makowski M, Smith DJ, Roberts PC, Beigel JH. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses. medRxiv. 2022 Jul 15. PMID: 35898343; PMCID: PMC9327623.
    Citations:    
  8. Julg B, Stephenson KE, Wagh K, Tan SC, Zash R, Walsh S, Ansel J, Kanjilal D, Nkolola J, Walker-Sperling VEK, Ophel J, Yanosick K, Borducchi EN, Maxfield L, Abbink P, Peter L, Yates NL, Wesley MS, Hassell T, Gelderblom HC, deCamp A, Mayer BT, Sato A, Gerber MW, Giorgi EE, Gama L, Koup RA, Mascola JR, Monczor A, Lupo S, Rolle CP, Arduino R, DeJesus E, Tomaras GD, Seaman MS, Korber B, Barouch DH. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat Med. 2022 06; 28(6):1288-1296. PMID: 35551291; PMCID: PMC9205771.
    Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
  9. Takuva S, Karuna ST, Juraska M, Rudnicki E, Edupuganti S, Anderson M, De La Grecca R, Gaudinski MR, Sehurutshi A, Orrell C, Naidoo L, Valencia J, Villela LM, Walsh SR, Andrew P, Karg C, Randhawa A, Hural J, Gomez Lorenzo MM, Burns DN, Ledgerwood J, Mascola JR, Cohen M, Corey L, Mngadi K, Mgodi NM. Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials. J Acquir Immune Defic Syndr. 2022 04 01; 89(4):405-413. PMID: 34923559; PMCID: PMC9555144.
    Citations:    Fields:    Translation:HumansCellsCTClinical Trials
  10. Sridhar S, Joaquin A, Bonaparte MI, Bueso A, Chabanon AL, Chen A, Chicz RM, Diemert D, Essink BJ, Fu B, Grunenberg NA, Janosczyk H, Keefer MC, Rivera M DM, Meng Y, Michael NL, Munsiff SS, Ogbuagu O, Raabe VN, Severance R, Rivas E, Romanyak N, Rouphael NG, Schuerman L, Sher LD, Walsh SR, White J, von Barbier D, de Bruyn G, Canter R, Grillet MH, Keshtkar-Jahromi M, Koutsoukos M, Lopez D, Masotti R, Mendoza S, Moreau C, Ceregido MA, Ramirez S, Said A, Tavares-Da-Silva F, Shi J, Tong T, Treanor J, Diazgranados CA, Savarino S. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. Lancet Infect Dis. 2022 05; 22(5):636-648. PMID: 35090638; PMCID: PMC8789245.
    Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
  11. Karuna S, Li SS, Grant S, Walsh SR, Frank I, Casapia M, Trahey M, Hyrien O, Fisher L, Miner MD, Randhawa AK, Polakowski L, Kublin JG, Corey L, Montefiori D. Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. PLoS Med. 2021 12; 18(12):e1003868. PMID: 34871308; PMCID: PMC8687542.
    Citations: 8     Fields:    Translation:Humans
  12. Campion SL, Brenna E, Thomson E, Fischer W, Ladell K, McLaren JE, Price DA, Frahm N, McElrath JM, Cohen KW, Maenza JR, Walsh SR, Baden LR, Haynes BF, Korber B, Borrow P, McMichael AJ. Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. J Clin Invest. 2021 12 01; 131(23). PMID: 34850742; PMCID: PMC8631594.
    Citations:    Fields:    Translation:HumansCellsCTClinical Trials
  13. Desjardins M, Mitre X, Sherman AC, Walsh SR, Cheng MP, Kanjilal S, Ho VT, Baden LR, Issa NC. Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant. Open Forum Infect Dis. 2021 Dec; 8(12):ofab504. PMID: 34909436; PMCID: PMC8664685.
    Citations: 1     
  14. Stephenson KE, Julg B, Tan CS, Zash R, Walsh SR, Rolle CP, Monczor AN, Lupo S, Gelderblom HC, Ansel JL, Kanjilal DG, Maxfield LF, Nkolola J, Borducchi EN, Abbink P, Liu J, Peter L, Chandrashekar A, Nityanandam R, Lin Z, Setaro A, Sapiente J, Chen Z, Sunner L, Cassidy T, Bennett C, Sato A, Mayer B, Perelson AS, deCamp A, Priddy FH, Wagh K, Giorgi EE, Yates NL, Arduino RC, DeJesus E, Tomaras GD, Seaman MS, Korber B, Barouch DH. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat Med. 2021 10; 27(10):1718-1724. PMID: 34621054; PMCID: PMC8516645.
    Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
  15. Stranix-Chibanda L, Yu C, Isaacs MB, Allen M, Andriesen J, Walsh SR. A retrospective analysis of incident pregnancy in phase 1 and 2a HIV-1 vaccine study participants does not support concern for adverse pregnancy or birth outcomes. BMC Infect Dis. 2021 Aug 11; 21(1):802. PMID: 34380464; PMCID: PMC8356543.
    Citations:    Fields:    Translation:HumansCells
  16. Walsh SR, Seaman MS. Broadly Neutralizing Antibodies for HIV-1 Prevention. Front Immunol. 2021; 12:712122. PMID: 34354713.
    Citations: 9     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  17. Axfors C, Schmitt AM, Janiaud P, Van't Hooft J, Abd-Elsalam S, Abdo EF, Abella BS, Akram J, Amaravadi RK, Angus DC, Arabi YM, Azhar S, Baden LR, Baker AW, Belkhir L, Benfield T, Berrevoets MAH, Chen CP, Chen TC, Cheng SH, Cheng CY, Chung WS, Cohen YZ, Cowan LN, Dalgard O, de Almeida E Val FF, de Lacerda MVG, de Melo GC, Derde L, Dubee V, Elfakir A, Gordon AC, Hernandez-Cardenas CM, Hills T, Hoepelman AIM, Huang YW, Igau B, Jin R, Jurado-Camacho F, Khan KS, Kremsner PG, Kreuels B, Kuo CY, Le T, Lin YC, Lin WP, Lin TH, Lyngbakken MN, McArthur C, McVerry BJ, Meza-Meneses P, Monteiro WM, Morpeth SC, Mourad A, Mulligan MJ, Murthy S, Naggie S, Narayanasamy S, Nichol A, Novack LA, O'Brien SM, Okeke NL, Perez L, Perez-Padilla R, Perrin L, Remigio-Luna A, Rivera-Martinez NE, Rockhold FW, Rodriguez-Llamazares S, Rolfe R, Rosa R, Røsjø H, Sampaio VS, Seto TB, Shahzad M, Soliman S, Stout JE, Thirion-Romero I, Troxel AB, Tseng TY, Turner NA, Ulrich RJ, Walsh SR, Webb SA, Weehuizen JM, Velinova M, Wong HL, Wrenn R, Zampieri FG, Zhong W, Moher D, Goodman SN, Ioannidis JPA, Hemkens LG. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021 04 15; 12(1):2349. PMID: 33859192.
    Citations: 96     Fields:    Translation:HumansCells
  18. Oganezova K, Fontana-Martinez EJ, Gothing JA, Pandit A, Kwara E, Yanosick K, Dragavon J, Goecker EA, Maenza J, Espy N, Tomaka F, Lavreys L, Allen M, D'Souza P, Hural J, Coombs RW, Dolin R, Seaman MS, Walsh SR, Baden LR. Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees. Open Forum Infect Dis. 2021 Jan; 8(1):ofaa606. PMID: 33511233; PMCID: PMC7813203.
    Citations:    
  19. Baden LR, Stieh DJ, Sarnecki M, Walsh SR, Tomaras GD, Kublin JG, McElrath MJ, Alter G, Ferrari G, Montefiori D, Mann P, Nijs S, Callewaert K, Goepfert P, Edupuganti S, Karita E, Langedijk JP, Wegmann F, Corey L, Pau MG, Barouch DH, Schuitemaker H, Tomaka F. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV. 2020 10; 7(10):e688-e698. PMID: 33010242; PMCID: PMC7529856.
    Citations: 24     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  20. Moodie Z, Walsh SR, Laher F, Maganga L, Herce ME, Naidoo S, Hosseinipour MC, Innes C, Bekker LG, Grunenberg N, Mann P, Yu C, deCamp AC, Miner MD, Yates NL, Heptinstall J, Mkhize NN, Dintwe O, Frahm N, Cohen KW, Allen M, Hutter J, Wagner R, Pantaleo G, McElrath MJ, Tomaras GD, Morris L, Montefiori DC, Andersen-Nissen E, Gray GE, Gilbert PB, Kublin JG. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Med. 2020 05; 17(5):e1003117. PMID: 32442195.
    Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
  21. Stephenson KE, Tan CS, Walsh SR, Hale A, Ansel JL, Kanjilal DG, Jaegle K, Peter L, Borducchi EN, Nkolola JP, Makoni T, Fogel R, Bradshaw C, Tyler A, Moseley E, Chandrashekar A, Yanosick KE, Seaman MS, Eckels KH, De La Barrera RA, Thompson J, Dawson P, Thomas SJ, Michael NL, Modjarrad K, Barouch DH. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2020 09; 20(9):1061-1070. PMID: 32618279.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  22. Stephenson KE, Wegmann F, Tomaka F, Walsh SR, Tan CS, Lavreys L, Ansel JL, Kanjilal DG, Jaegle K, Nkolola JP, Peter L, Fogel R, Bradshaw C, Tyler A, Makoni T, Howe L, Quijada D, Chandrashekar A, Bondzie EA, Borducchi EN, Yanosick KE, Hendriks J, Nijs S, Truyers C, Tolboom J, Zahn RC, Seaman MS, Alter G, Stieh DJ, Pau MG, Schuitemaker H, Barouch DH. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). Lancet HIV. 2020 06; 7(6):e410-e421. PMID: 32078815; PMCID: PMC7297076.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  23. Cohen YZ, Butler AL, Millard K, Witmer-Pack M, Levin R, Unson-O'Brien C, Patel R, Shimeliovich I, Lorenzi JCC, Horowitz J, Walsh SR, Lin S, Weiner JA, Tse A, Sato A, Bennett C, Mayer B, Seaton KE, Yates NL, Baden LR, deCamp AC, Ackerman ME, Seaman MS, Tomaras GD, Nussenzweig MC, Caskey M. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLoS One. 2019; 14(8):e0219142. PMID: 31393868; PMCID: PMC6687118.
    Citations: 25     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  24. Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis. 2018 07 13; 218(4):633-644. PMID: 29669026; PMCID: PMC6047429.
    Citations: 18     Fields:    Translation:HumansCells
  25. Cheng MP, Pandit A, Antin JH, Walsh SR, Huynh D, Ghobrial IM, Baden LR, Marty FM, Issa NC. Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. Blood Adv. 2018 06 12; 2(11):1272-1276. PMID: 29871892.
    Citations: 3     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  26. Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018 02 10; 391(10120):563-571. PMID: 29217375; PMCID: PMC5884730.
    Citations: 91     Fields:    Translation:HumansCellsCTClinical Trials
  27. Liu F, Haeger CM, Dieffenbach PB, Sicard D, Chrobak I, Coronata AM, Suárez Velandia MM, Vitali S, Colas RA, Norris PC, Marinkovic A, Liu X, Ma J, Rose CD, Lee SJ, Comhair SA, Erzurum SC, McDonald JD, Serhan CN, Walsh SR, Tschumperlin DJ, Fredenburgh LE. Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertension. JCI Insight. 2016 Jun 02; 1(8). PMID: 27347562.
    Citations: 39     Fields:    
  28. Baden LR, Karita E, Mutua G, Bekker LG, Gray G, Page-Shipp L, Walsh SR, Nyombayire J, Anzala O, Roux S, Laher F, Innes C, Seaman MS, Cohen YZ, Peter L, Frahm N, McElrath MJ, Hayes P, Swann E, Grunenberg N, Grazia-Pau M, Weijtens M, Sadoff J, Dally L, Lombardo A, Gilmour J, Cox J, Dolin R, Fast P, Barouch DH, Laufer DS. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Ann Intern Med. 2016 Mar 01; 164(5):313-22. PMID: 26833336; PMCID: PMC5034222.
    Citations: 46     Fields:    Translation:HumansCells
  29. Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. J Infect Dis. 2016 Feb 15; 213(4):541-50. PMID: 26475930; PMCID: PMC4721914.
    Citations: 14     Fields:    Translation:HumansCells
  30. Baden LR, Liu J, Li H, Johnson JA, Walsh SR, Kleinjan JA, Engelson BA, Peter L, Abbink P, Milner DA, Golden KL, Viani KL, Stachler MD, Chen BJ, Pau MG, Weijtens M, Carey BR, Miller CA, Swann EM, Wolff M, Loblein H, Seaman MS, Dolin R, Barouch DH. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis. 2015 Feb 15; 211(4):518-28. PMID: 25165165; PMCID: PMC4318919.
    Citations: 40     Fields:    Translation:HumansCellsCTClinical Trials
  31. Baden LR, Walsh SR, Seaman MS, Johnson JA, Tucker RP, Kleinjan JA, Gothing JA, Engelson BA, Carey BR, Oza A, Bajimaya S, Peter L, Bleckwehl C, Abbink P, Pau MG, Weijtens M, Kunchai M, Swann EM, Wolff M, Dolin R, Barouch DH. First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis. 2014 Oct 01; 210(7):1052-61. PMID: 24719474; PMCID: PMC4168302.
    Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
  32. Chalkias S, Mackenzie MR, Gay C, Dooley C, Marty FM, Moss RB, Li T, Routh RL, Walsh SR, Tan CS. DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. Transpl Infect Dis. 2014 Feb; 16(1):141-4. PMID: 24383501.
    Citations: 24     Fields:    Translation:Humans
  33. Walsh SR, Wilck MB, Dominguez DJ, Zablowsky E, Bajimaya S, Gagne LS, Verrill KA, Kleinjan JA, Patel A, Zhang Y, Hill H, Acharyya A, Fisher DC, Antin JH, Seaman MS, Dolin R, Baden LR. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis. 2013 Jun 15; 207(12):1888-97. PMID: 23482644; PMCID: PMC3654753.
    Citations: 25     Fields:    Translation:HumansCellsPHPublic Health
  34. Walsh SR, Seaman MS, Grandpre LE, Charbonneau C, Yanosick KE, Metch B, Keefer MC, Dolin R, Baden LR. Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses. Vaccine. 2012 Dec 17; 31(1):114-9. PMID: 23142302.
    Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
  35. Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A, Alter G, Chung A, Dugast AS, Frahm N, McElrath MJ, Wenschuh H, Reimer U, Seaman MS, Pau MG, Weijtens M, Goudsmit J, Walsh SR, Dolin R, Baden LR. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis. 2013 Jan 15; 207(2):248-56. PMID: 23125443; PMCID: PMC3532832.
    Citations: 67     Fields:    Translation:HumansCells
  36. Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick KE, Perry J, Zablowsky E, Abbink P, Peter L, Iampietro MJ, Cheung A, Pau MG, Weijtens M, Goudsmit J, Swann E, Wolff M, Loblein H, Dolin R, Barouch DH. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis. 2013 Jan 15; 207(2):240-7. PMID: 23125444; PMCID: PMC3532831.
    Citations: 88     Fields:    Translation:HumansCells
  37. Fredenburgh LE, Velandia MM, Ma J, Olszak T, Cernadas M, Englert JA, Chung SW, Liu X, Begay C, Padera RF, Blumberg RS, Walsh SR, Baron RM, Perrella MA. Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsis. J Immunol. 2011 Nov 15; 187(10):5255-67. PMID: 21967897; PMCID: PMC3208135.
    Citations: 44     Fields:    Translation:HumansAnimalsCells
  38. Walsh SR, Dolin R. Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines. 2011 Aug; 10(8):1221-40. PMID: 21854314.
    Citations: 44     Fields:    Translation:HumansAnimalsCells
  39. Wilck MB, Seaman MS, Baden LR, Walsh SR, Grandpre LE, Devoy C, Giri A, Kleinjan JA, Noble LC, Stevenson KE, Kim HT, Dolin R. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis. 2010 May 01; 201(9):1361-70. PMID: 20350191; PMCID: PMC3016847.
    Citations: 39     Fields:    Translation:HumansCells
  40. Seaman MS, Wilck MB, Baden LR, Walsh SR, Grandpre LE, Devoy C, Giri A, Noble LC, Kleinjan JA, Stevenson KE, Kim HT, Dolin R. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J Infect Dis. 2010 May 01; 201(9):1353-60. PMID: 20350190; PMCID: PMC3023456.
    Citations: 19     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  41. Walsh SR, Gillis J, Peters B, Mothé BR, Sidney J, Sette A, Johnson RP. Diverse recognition of conserved orthopoxvirus CD8+ T cell epitopes in vaccinated rhesus macaques. Vaccine. 2009 Aug 06; 27(36):4990-5000. PMID: 19531389.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  42. Walsh SR and Johnson RP. Vaccinia folliculitis after primary Dryvax vaccination. Infectious Diseases in Clinical Practice. 2007; 15(2):132-134. View Publication.
  43. Walsh SR, Parada NA. Images in clinical medicine. Uremic frost. N Engl J Med. 2005 Mar 31; 352(13):e13. PMID: 15800220.
    Citations: 1     Fields:    Translation:Humans
  44. Walsh SR, Ferraro MJ, Durand ML. Clindamycin-resistant Streptococcus pyogenes: report of a case. Diagn Microbiol Infect Dis. 2004 Jul; 49(3):223-5. PMID: 15246514.
    Citations: 1     Fields:    Translation:HumansCells
  45. Ellerin TB, Walsh SR, Hooper DC. Recurrent meningitis of unknown aetiology. Lancet. 2004 May 29; 363(9423):1772. PMID: 15172776.
    Citations: 3     Fields:    Translation:HumansCells
  46. Walsh SR, Bhardwaj N, Gandhil RT. Dendritic cells and the promise of therapeutic vaccines for human immunodeficiency virus (HIV)-1. Curr HIV Res. 2003 Apr; 1(2):205-16. PMID: 15043203.
    Citations: 8     Fields:    Translation:HumansCells
  47. Walsh SR. Viral genomes. CMAJ. 2003 Mar 04; 168(5):544. PMID: 12615744; PMCID: PMC149242.
    Citations:    Fields:    Translation:HumansCells
  48. Fraser FC, Teebi AS, Walsh S, Pinsky L. Poland sequence with dextrocardia: which comes first? Am J Med Genet. 1997 Dec 12; 73(2):194-6. PMID: 9409872.
    Citations: 6     Fields:    Translation:Humans
  49. Duncan R, Chen Z, Walsh S, Wu S. Avian reovirus-induced syncytium formation is independent of infectious progeny virus production and enhances the rate, but is not essential, for virus-induced cytopathology and virus egress. Virology. 1996 Oct 15; 224(2):453-64. PMID: 8874506.
    Citations: 25     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Walsh's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (188)
Explore
_
Co-Authors (34)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.